Subcutaneous · Amylin analog
KBP-089
1 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
1
Active
0
Recruiting
0
Completed
0
Sites
1
Countries
1
Endpoints
24
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Trials by status
Terminated
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
15
Glycemic / diabetes
4
Cardiometabolic biomarkers
3
Weight & body composition
1
Other (unclassified)
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT03907202A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM | KBP-089 Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 1 | Terminated | 1 | Dec 2019 | — |